In alignment with the JLCS Guidelines, ICI monotherapy was the most commonly used first-line treatment for patients with advanced NSCLC with high PD-L1 expression and without actionable genomic alterations following the introduction of immunotherapy in Japan. This evidence concerns the gene CD274 and non-small cell lung carcinoma.